Acute myeloid leukemia (AML) with t(8;21) is considered a favorable cytogenetic subgroup, with a 3-year survival of over 80% according to recent results from our group and others [1] [2] [3] . Recently, homoharringtonine combined aclarubicin and cytarabine (HAA) has been demonstrated to achieve a high complete remission (CR) rate and provide a survival advantage in patients with acute myeloid leukemia (AML) [4, 5] . According to a subgroup analysis, HAA showed significantly strong activity on t(8;21) and inv (16) 
supports previous results from some single-center studies [6, 7] . Moreover, as a salvage treatment, the HAA regimen has achieved a 90% CR rate in refractory/relapsed t (8;21) and inv(16)/t(16;16) AML [8] . Our data showed that one cycle of HAA treatment can yield a 93% (28/30) CR rate in de novo t(8;21) AML patients [9] . These results suggest that the HAA regimen is highly effective against t(8;21) AML.
To date, the underlying mechanisms by which HAA kills t(8;21) AML cells remain unclear. Homoharringtonine is an alkaloid derived from trees of the genus Cephalotaxus, having been used for more than 30 years to treat AML in China. The antileukemic effects of homoharringtonine are primarily based on the inhibition of protein synthesis, which induces differentiation, inhibits proliferation, and promotes apoptosis in leukemic cells [10] [11] [12] [13] . Homoharringtonine also has a synergistic relationship with cytarabine and aclarubicin [11] . Wang et al. confirmed that combining homoharringtonine with aclarubicin can result in synergistic cytotoxicity in THP-1and Kasumi-1 cells in vitro and in vivo [13] . Combining homoharringtonine and aclarubicin simultaneously inhibited PI3K/AKT and WNT/β--catenin signaling in AML cells [13] . However, the mechanism of action of HAA in t (8;21) AML has yet to be explored. Therefore, we investigated the mechanism of the robust antileukemia effect of HAA on t(8;21)AML in vitro.
Methods

Cell lines and cell cultures
The AML cell lines SKNO-1 and Kasumi-1 were cultured in RPMI-1640 (Gibco, Billings, MT, USA) supplemented with 10% fetal bovine serum (Gibco). All cell lines were grown at 37°C in a 5% CO 2 atmosphere. Cell viability was assessed by triplicate counting of trypan blue dyeexcluding cells under light microscopy.
Reagents and antibodies
Homoharringtonine was provided by Minsheng Pharmaceutical (Hangzhuo, China). Cytarabine was provided by Pfizer Pharmaceuticals (Nerviano, Italy). Aclarubicin was obtained from Wanle Pharmaceutical (Shenzhen, China). Fludarabine was provided by Pfizer Pharmaceuticals (Fuyang, China). Caspase-3 and PARP antibodies were obtained from Abcam (Epitomics, Burlingame, CA, USA; Cambridge, UK). The antibody against ETO was obtained from Cell Signaling Technology (Danvers, USA).
Growth inhibition assay
The inhibition of Kasumi-1 and SKNO-1 cell growth was evaluated by CCK-8 assay (Dojindo Laboratories, Kumamoto, Japan). Briefly, 96-well plates were seeded with 1 × 10 5 cells per well and treated with various combinations of homoharringtonine, aclarubicin, and cytarabine. After 24 h or 48 h in culture, 10 μL of CCK-8 solution was added to each well. The samples were incubated at 37°C for 4-6 h, and absorbance was measured at 450 nm using a microplate reader (Thermo Multiskan MK3, Waltham, MA, USA). Each sample was assayed with three replicates per assay, and cell-line experiments were carried out in triplicate.
Evaluation of apoptosis
Cells were treated with different combinations of reagents or equal volumes of DMSO for 12 h, harvested and washed twice with phosphate buffered saline (PBS; Gibco), resuspended in binding buffer and stained with Annexin V-APC/7-AAD according to the manufacturer's instructions (BD Pharmingen). A total of 5 μL of Annexin V-FITC (BD Pharmingen, Torreyana Road, San Diego, CA, USA) and 5 μL of PI were added to the cell suspension. The data were expressed as the percentages of early apoptotic cells (Annexin V-APC + /7-AAD−) and late apoptotic cells (Annexin V-APC + /7-AAD+). Samples were analyzed on a FACSCalibur flow cytometer (BD Bioscience, San Jose, CA) equipped with CellQuest Pro software (BD Bioscience). For each sample, at least 1 × 10 5 events were acquired for downstream analysis.
Hoechst staining
SKNO-1 and Kasumi-1 cells were treated with different combinations of reagents or with equal volumes of DMSO for 12 h. Cells were then permeabilized with 0.5% Triton X-100 for 30 min, washed with PBS, stained with 10 μg/mL Hoechst for 30 min, and washed with PBS. Nuclear morphology was observed immediately via fluorescence microscopy (BX51, Olympus, Tokyo, Japan).
Western blot assay
Cells were harvested, ground in liquid nitrogen, lysed in lysis buffer (1% Triton X-100, 0.015 mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L phenylmethanesulfonyl fluoride (PMSF) and 10 g/ mL each of leupeptin, aprotinin, and pepstatin A) and then incubated on ice for 30 min. Lysates were centrifuged at 12,000 g for 10 min at 4°C. Supernatants were mixed with one-quarter volume of 4 × SDS sample buffer, boiled for 10 min and then separated by SDS-PAGE on 10-12% gels. After electrophoresis, proteins were transferred to nitrocellulose (NC) membranes (Millipore Corporation, Bedford, MA, USA), blocked for 1 h with 5% non-fat milk powder in TBST buffer (20 mmol/L Tris-HCl, pH 7.6, 150 mmol/L NaCl, and 0.05% Tween-20) and then incubated with primary antibodies at 1:1000 dilution overnight at 4°C. The membranes were washed three times with TBST and then incubated with secondary antibody at 1:5000 dilution for 1 h at RT. After extensive washing, proteins were visualized using an ECL-Plus Kit (Thermo Scientific, Rockford, IL, USA), and blots were exposed to Kodak radiographic film.
Statistical analysis
Data were expressed as the mean ± standard deviation (SD). The half-maximal inhibitory concentrations (IC50) were calculated using GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA). The combination index (CI) was calculated using the Chou-Talalay method (Calcusyn software, Biosoft, San Diego, CA) to ascertain whether the effects of the drug combinations were synergistic (CI < 1), additive (CI = 1), or antagonistic (CI > 1). Categorical variables were compared using Fisher's exact test or the chi-square test, and continuous variables were compared using the Wilcoxon rank sum test. P < 0.05 was considered statistically significant. (51.37 ± 7.87 nmol/L) respectively (n = 3). The inhibition of Kasumi-1 and SKNO-1 cell growth was concentration-dependent. The CCK-8 assay showed dosedependent growth inhibition by homoharringtonine (HHT), cytarabine (Ara-C) and aclarubicin (ACR) (P < 0.05). The growth-inhibition effect of HAA on SKNO-1 and Kasumi-1 cells was stronger than that of any two-drug combination at 24 h (Fig. 1A, 2B ) (P < 0.001). Using Calcusyn 2.0, we found that HAA (1:2.86:2.5) also showed the strongest synergistic effect with CI values of (X and Y) for SKNO-1 and Kasumi-1 cells, respectively (Fig. 1B-E and 2B-E) . (Fig. 3,  n = 3) . Moreover, pretreatment with 50 μmol/L of the caspase-3 inhibitor Q-DEVD-OPh (QDO) for 12 h significantly suppressed HAA-induced apoptosis. Hoechst staining also showed a higher number of condensed and/ or fragmented nuclei in Kasumi-1 cells treated with HAA compared with any individual drug or pairwise combination of drugs (Fig. 4, n = 3 ).
Homoharringtonine combined with cytarabine and aclarubicin synergistically induced cleavage of the AML1-ETO (AE) oncoprotein in Kasumi-1 and SKNO-1 cells
The concentrations of homoharringtonine, cytarabine, and aclarubicin were 36, 103, and 90 nmol/L respectively. Cleavage of the AML1-ETO (AE) oncoprotein in Kasumi-1 and SKNO-1 cells treated with HAA was higher than that observed for any individual drug or pairwise combination of drugs (Fig. 5, n = 3) . Western blotting revealed six truncated AEs (ΔAEs) following treatment with the individual drugs or the various drug combinations, which was not markedly in the combination of fludarabine (95 nmol/L) adding cytarabine (103 nmol/L) (Fig. 5F ).
Pretreatment with 50 μmol/L of the caspase-3 inhibitor Q-DEVD-OPh (QDO) for 12 h abrogated AE cleavage and the generation of ΔAE (Fig. 5G, H, n = 3) . We further analyzed the expression of caspase-3, cleaved caspase-3 (Δcaspase-3), PARP, and cleaved PARP (ΔPARP). The activation of caspase-3 and the degradation of PARP were significantly inhibited in each group except for that treated with the combination of homoharringtonine and aclarubicin (Fig. 6, n = 3 ).
Discussion
Our study showed that, compared with single drugs or two-drug combinations, HAA synergistically induced apoptosis in t(8;21) leukemia cells and triggered the caspase-3-mediated cleavage of the AML1-ETO oncoprotein. This study provides in vitro evidence to explain the high efficacy of HAA treatment in t(8;21) AML patients. The CI of HAA at the median effective dose (ED50) was 0.52 for SKNO-1 cells, 0.52 for Kasumi-1 cells. The high efficacy of HAA against t(8;21) AML may be due to the different mechanisms by which homoharringtonine, cytarabine, and aclarubicin kill leukemia cells. Homoharringtonine is an alkaloid derived from trees of the genus Cephalotaxus. The antileukemic effects of homoharringtonine are primarily based on the inhibition of protein synthesis, which induces differentiation, inhibits proliferation, and promotes apoptosis in leukemic cells [14, 15] . The cytotoxicity of homoharringtonine is cell-cycle specific, primarily affecting cells in the G1 and G2 phases [16] . Moreover, homoharringtonine has been demonstrated to have significant synergistic effects with cytarabine [13, 17] .
Aclarubicin, an alternative to daunorubicin, showed promising antileukemic efficacy in combination with cytarabine [18] . Homoharringtonine, aclarubicin and cytarabine may also have no cross-resistance, which may partially explain their potent antileukemia activity.
We wanted to elucidate the detailed events that occur during HAA treatment in leukemia cells with t(8;21). We found that HAA showed strongly inhibited growth and induced apoptosis in SKNO-1 and Kasumi-1 cells compared with individual drugs or two-drug combinations. Our results support those of previous reports in which homoharringtonine, either alone or combined with aclarubicin, promoted apoptosis in Kasumi-1, or primary AML cells.
The caspase-3-mediated cleavage of the AML1-ETO oncoprotein was shown to be a major molecular mechanism of HAA activity in leukemia cells with t(8;21). When caspase-3 action was blocked by an inhibitor, these cleaved fragments disappeared, strongly suggesting that caspase-3 either directly or indirectly contributes to apoptosis-related cleavage. Chen and coworkers also reported that the AML1-ETO oncoprotein was degraded in parallel with caspase-3 activation in apoptotic Kasumi-1 cells induced by eriocalyxin B and oridonin [19, 20] . Caspase-3 activation, which is essential for leukemia cell apoptosis, leads to AML1-ETO oncoprotein cleavage, resulting in the loss of ubiquitination sites and the generation of a 70-kDa degradable form of AML1-ETO (ΔAE) [20, 21] . When SKNO-1 and Kasumi-1 were treated with mouse monoclonal antiFas IgM antibody CH11, or were exposed to a germicidal lamp providing predominantly 254-nm UV-C light, 70, 49, 40, and 25 kDa were detected by anti-ETO antibody during apoptosis [22] . However, our study found that, when HAA was used, 35 and 15 kDa ΔAE were detected, and the generation of 15 kDa ΔAE could be inhibited by caspase-3 inhibitor QDO (Fig. 5) . ΔAE interacts with AML1-ETO and interferes with the trans-regulatory functions of the remaining AML1-ETO oncoprotein [22] . These results may partially explain why t(8;21) leukemia cells were more sensitive to HAA.
Our study has certain limitations. Apart from t(8;21) AML or primary cells from t(8;21) AML patients, no other types of AML cell lines were used in this study. This deficit may be improved in the future. We also have not included our clinical data on the efficacy of HAA treatment on t(8;21)AML patients, which are described separately.
In summary, our study suggests that HAA synergistically induces apoptosis in t(8;21) leukemia cells and triggers the caspase-3-mediated cleavage of the AML1-ETO oncoprotein, thereby providing new insights into the biology and treatment of t(8;21)AML.
